Skip to main content

Advertisement

SpringerLink
Log in

Differenzialtherapie beim metastasierenden Nierenzellkarzinom

Treatment optimization in metastatic renal cell carcinoma

  • Aktuelle Therapie
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Im Jahr 2006 wurden Sorafenib und Sunitinib in Europa für die Behandlung von metastasierenden Nierenzellkarzinomen (mNZK) zugelassen. Weitere innovative Substanzen, über die noch keine Daten veröffentlicht wurden, sind auf dem Markt zu erwarten. Sie werden eine ganze Palette individueller therapeutischer Optionen ermöglichen. Die Grundlagen der primären chirurgischen Verfahren zur Tumor- und Metastasenresektion bleiben hierbei unberührt. Da ein anerkannter Algorithmus für diese neue Medikamentenklasse bisher fehlt, werden Empfehlungen zur mNZK-Therapie in der klinischen Praxis notwendig. Der vorgestellte Behandlungsalgorithmus basiert auf Ergebnissen der evidenzbasierten Medizin in Verbindung mit Parametern, die sich aus den im Jahr 2007 beim ASCO-Kongress vorgestellten Daten ergeben haben – und letztendlich auf breiten Erfahrungen bei der Behandlung von mNZK-Patienten.

Abstract

In 2006 the new compounds Sorafenib and Sunitinib were approved in Europe for the treatment of advanced renal cell carcinoma (mRCC). Additional innovative substances are to be expected on the market for which data have not yet been published and will provide physicians with a whole array of individual therapeutic options. Principles of primary surgical procedures for tumor and metastasis resection remain untouched. An accepted algorithm for the new drug entities has, however, been missing and it is felt that recommendations on how mRCC should be treated in clinical practice are needed. The suggested treatment algorithm is based on results from evidence-based medicine together with parameters which resulted in the approval of recent data announced at the ASCO congress in 2007 and, last but not least, on wide experience in treating mRCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Atzpodien J et al. (2005) Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. Cancer Biother Radiopharm 20 (4): 410–416

    Article  PubMed  CAS  Google Scholar 

  2. Bordin V et al. (2000) Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int 64 (1): 3–8

    Article  PubMed  CAS  Google Scholar 

  3. Bukowski RM et al. (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5023, Präsentation

  4. Coppin C et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1: CD001425

    PubMed  Google Scholar 

  5. Dham A et al. (2007) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5106, Präsentation

  6. Dutcher J et al. (2007) Correlation of Survival With Tumor Histology, Age and Prognostic-Risk Group for Previously Untreated Patients With Advanced Renal Cell Carcinoma Receiving Temsirolimus or Interferon Alpha. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5033, Präsentation

  7. Escudier B (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S:LAB3, Präsentation

  8. Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2): 125-134

    Article  PubMed  CAS  Google Scholar 

  9. George DJ et al. (2007) Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5035, Präsentation

  10. Gore ME et al. (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5010, Präsentation

  11. Houk BE et al. (2007) Esposure-response of Sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKDP) approach. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5027

  12. Hudes G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (22): 2271–2281

    Article  PubMed  CAS  Google Scholar 

  13. Jonasch E et al. (2007) Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5104

  14. Knox JJ et al. (2007) The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5011, Präsentation

  15. Motzer RJ et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (1): 16–24

    Article  PubMed  CAS  Google Scholar 

  16. Motzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (21): 2516–2524

    Article  PubMed  CAS  Google Scholar 

  17. Motzer RJ et al. (2007) Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S,2007:5024, Präsentation

  18. Motzer RJ et al. (2007) Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2): 115–124

    Article  PubMed  CAS  Google Scholar 

  19. Plantade A et al. (2007) Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5037, Präsentation

  20. Srinivas Set al. (2007) Continuous Daily Administration of Sunitinib in Patients With Cytokine-refractory Metastatic Renal Cell Carcinoma: Updated Results. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5040, Präsentation

  21. Sablin MP et al. (2007) Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5038, Präsentation

  22. Szczylik C et al. (2007) randomized rhase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S: 5025, Präsentation

  23. Wilhelm SM et al. (2004) BAY 43–9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Research 64: 7099–7109

    Article  PubMed  CAS  Google Scholar 

  24. Wolter P et al. (2007) Sunitinib and Hypothyroidism. N Eng J Med 356 (15): 1580–1581

    Article  CAS  Google Scholar 

  25. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (5): 427–434

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Vortragshonorare und advisory board von Bayer, Roche, Pfizer.

Author information

Authors and Affiliations

  1. Klinikum Region Hannover GmbH, Krankenhaus Siloah, Medizinische Klinik III, Roesebeckstraße 15, 30449, Hannover, Deutschland

    H. Kirchner

  2. Klinik und Poliklinik für Urologie, UKE, Hamburg, Deutschland

    H. Heinzer

  3. Urologische Klinik, Charite – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Deutschland

    J. Roigas

  4. Praxis und Tagesklinik für Internistische Onkologie, Recklinghausen, Deutschland

    F. Overkamp

Authors
  1. H. Kirchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Heinzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Roigas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Overkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Kirchner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirchner, H., Heinzer, H., Roigas, J. et al. Differenzialtherapie beim metastasierenden Nierenzellkarzinom. Onkologe 14, 191–197 (2008). https://doi.org/10.1007/s00761-007-1314-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-007-1314-9

Schlüsselwörter

Keywords

Search

Navigation